Search All News
Lecanemab, marketed as Leqembi, is the first drug for Alzheimer’s disease to receive approval on the basis of clinically slowing the progression of Alzheimer’s disease.
Attending a high school with a high number of teachers with graduate training was the clearest predictor of the impact of school quality on late-life cognition, researchers found.
Columbia Nursing researchers are using AI analysis of voice recordings to find a quick, inexpensive way to screen home care patients for early dementia.
Columbia neurologists are investigating a set of blood tests that, used in combination with memory tests, may help physicians correctly diagnose Alzheimer disease in low-resource environments.
- March 31, 2023
Amyloid sparks an alliance between two proteins in the brain that can potentially explain up to half of the gene changes that occur in Alzheimer’s.
- May 24, 2022
A gene called FMNL2 may explain why people with hypertension, diabetes, heart disease, or obesity have a greater risk of developing Alzheimer's disease.
- February 15, 2022
One of the cell's most common proteins may become too old and too stable in Alzheimer’s disease, altering neuronal activity and impairing memory.
- March 30, 2021
In people with dementia, delirium during COVID-19 is more common but deaths from COVID-19 are not disproportionately higher, finds a new study.
- November 25, 2020
A new Columbia study suggests that malfunctioning endosomes—a central trafficking station inside neurons—are commonly involved in the appearance of Alzheimer’s disease.
- November 12, 2020
Ancient parts of the brain may hold secrets that help explain the drive to eat and how eating may affect brain health. Sabrina Diano, the new Institute of Human Nutrition director, is investigating.
- October 21, 2020
A new study of Alzheimer’s genes suggests the disease in Blacks and whites is largely the same, but genetic changes that increase the risk of developing the disease differ between the two groups.